Oral versus intramuscular methotrexate in juvenile chronic arthritis

A. Ravelli, V. Gerloni, F. Corona, F. Falcini, L. Lepore, R. De Sanctis, F. Zulian, A. Buoncompagni, M. L. Sardella, G. G. Strano, M. Alessio, F. Fantini, M. Bardare, A. Martini

Research output: Contribution to journalArticlepeer-review


Objective: To compare the efficacy and safety of methotrexate (MTX) after oral and intramuscular administration in children with juvenile chronic arthritis (JCA). Methods: Pediatric rheumatology centers in Italy participated in this short-term, prospective, open trial. Each investigator was allowed to choose the oral or intramuscular route of administration according to his personal preference in everyday clinical practice. Patients enrolled by each center were given MTX through the same method of administration. All patients received 10 mg/m2 of MTX each week for six months. Results: A total of 257 patients with JCA (127 treated orally and 130 intramuscularly) were enrolled in the trial by 11 Italian centers. The response rate after 6 months of MTX therapy was 58% in the oral and 61% in the intramuscular cohort. The frequency of adverse side effects did not differ significantly between the two treatment groups. Conclusion: The results of this study suggest that MTX at the conventional dose regimen is equally effective and has a similar safety profile in children with JCA when administered orally or by intramuscular injections.

Original languageEnglish
Pages (from-to)181-183
Number of pages3
JournalClinical and Experimental Rheumatology
Issue number2
Publication statusPublished - 1998


  • Juvenile chronic arthritis
  • Methotrexate

ASJC Scopus subject areas

  • Rheumatology
  • Immunology


Dive into the research topics of 'Oral versus intramuscular methotrexate in juvenile chronic arthritis'. Together they form a unique fingerprint.

Cite this